Johnson & Johnson SPINEOTHER — Sales to customers (Note 9) decreased by 3.9% to $1.40B in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 0.4%, from $1.39B to $1.40B. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates growing market adoption or successful product launches in the orthopedic sector, while a decrease may signal competitive pressure or reduced procedure volumes.
This metric represents the total revenue generated from the sale of products within the spine, sports medicine, and rela...
Comparable to revenue segments for orthopedic and surgical device divisions at major medical technology competitors.
jnj_segment_spine_sports_other_sales_to_customers_note_9| Q2 '21 | Q3 '21 | Q4 '21 | Q2 '22 | Q3 '22 | Q4 '22 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.41B | $1.55B | $1.41B | $1.42B | $1.45B | $1.42B | $1.46B | $1.42B | $1.50B | $1.49B | $1.39B | $1.34B | $1.45B | $1.40B |
| QoQ Change | — | +9.9% | -9.1% | +0.9% | +1.8% | -2.1% | +2.9% | -2.6% | +5.9% | -1.1% | -6.4% | -3.6% | +8.3% | -3.9% |
| YoY Change | — | — | — | +0.8% | -6.7% | +0.4% | +2.5% | -1.9% | — | +2.0% | -2.0% | -10.8% | -2.2% | +0.4% |
We use cookies for analytics. See our Privacy and Cookie Policy.